Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations: Current Medical Research and Opinion: Vol 29, No 12
Lars Schlichting's email & phone | CRS Clinical Research Services Andernach GMBH's Senior Director Business Development email
![Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single‐Center Open‐Label, Randomized Crossover Studies in Healthy Japanese Volunteers - Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single‐Center Open‐Label, Randomized Crossover Studies in Healthy Japanese Volunteers -](https://accp1.onlinelibrary.wiley.com/cms/asset/2ccd59f8-4efc-46b8-8448-e4724c95c4ab/cpdd846-fig-0002-m.jpg)
Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single‐Center Open‐Label, Randomized Crossover Studies in Healthy Japanese Volunteers -
![CRS Expands Its Capacity for Clinical Trials and Enters into Strategic Partnership with Bayer | Business Wire CRS Expands Its Capacity for Clinical Trials and Enters into Strategic Partnership with Bayer | Business Wire](https://mms.businesswire.com/media/20130619006138/en/373429/21/CRS_long_version_ohneStandort.jpg)
CRS Expands Its Capacity for Clinical Trials and Enters into Strategic Partnership with Bayer | Business Wire
![Mischo Kursar's email & phone | CRS Clinical Research Services Andernach GMBH's Senior Director Corporate Development and Strategic Account Lead email Mischo Kursar's email & phone | CRS Clinical Research Services Andernach GMBH's Senior Director Corporate Development and Strategic Account Lead email](https://d1hbpr09pwz0sk.cloudfront.net/profile_pic/micho-bursac-642f108c.jpg)